Rinne U K, Mölsä P
Neurology. 1979 Dec;29(12):1584-9. doi: 10.1212/wnl.29.12.1584.
Plasma levodopa and therapeutic responses to treatment with levodopa in combination with benserazide or carbidopa were studied in 49 patients with Parkinson disease not previously treated with levodopa in a blind randomized crossover trial. The treatment periods were 12 weeks; similar dosage schedules were used, with doses that induced equal levels of plasma levodopa in both combinations. In pretrial studies of plasma levodopa responses, 200 mg of levodopa and 50 mg of benserazide was equal to 250 mg of levodopa combined with 25 mg of carbidopa. Equal plasma levodopa responses to both combinations were also found during the trial. There was no significant difference between the treatment groups in beneficial effects on parkinsonian disability and individual symptoms or in the frequency of involuntary movements. However, nausea and vomiting occurred significantly more often during treatment with levodopa and carbidopa than during treatment with levodopa and benserazide. This difference was probably due to inadequate inhibition of peripheral decarboxylase inhibitor by the 1:10 ratio of carbidopa to levodopa.
在一项针对49例未曾接受过左旋多巴治疗的帕金森病患者的盲法随机交叉试验中，研究了血浆左旋多巴以及左旋多巴与苄丝肼或卡比多巴联合治疗的疗效。治疗期为12周；采用了相似的给药方案，两种联合用药中诱导血浆左旋多巴水平相等的剂量。在血浆左旋多巴反应的预试验研究中，200mg左旋多巴与50mg苄丝肼等同于250mg左旋多巴与25mg卡比多巴联合使用。试验期间也发现两种联合用药的血浆左旋多巴反应相同。治疗组在对帕金森病残疾和个体症状的有益作用或不自主运动的频率方面没有显著差异。然而，与左旋多巴和苄丝肼治疗期间相比，左旋多巴和卡比多巴治疗期间恶心和呕吐的发生率明显更高。这种差异可能是由于卡比多巴与左旋多巴1:10的比例对外周脱羧酶抑制剂的抑制不足所致。
